Qyuns Therapeutics Co Ltd (2509.HK)
HKD 11.24
(1.81%)
HKD 11.24
(1.81%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 14.75 Million | 9.66 Million | 21.34 Million |
| Cost of Revenue | - | 35.51 Million | 30.9 Million |
| Gross Profit | 14.75 Million | -25.85 Million | -9.55 Million |
| Operating Expenses | 519.26 Million | 352.67 Million | 210.96 Million |
| Selling, General and Administrative Expenses | 164.59 Million | 81.96 Million | 52.67 Million |
| Research and Development Expenses | 364.4 Million | 270.7 Million | 158.29 Million |
| Other Expenses | -9.73 Million | 413 Thousand | 1.27 Million |
| Cost and Expenses | 515.4 Million | 388.18 Million | 241.87 Million |
| Operating Income | -504.51 Million | -388.18 Million | -241.87 Million |
| Interest Expense | 16.82 Million | 18.69 Million | 17.84 Million |
| Income Tax Expense | -73 Thousand | -84.89 Thousand | -87.98 Thousand |
| Earnings before Tax | -521.33 Million | -363.26 Million | -514.07 Million |
| Net Income | -507.74 Million | -346.75 Million | -359.48 Million |
| Earnings Per Share Basic | -2.47 | -1.56 | -1.62 |
| Earnings Per Share Diluted | -2.47 | -1.56 | -1.62 |
| Weighted Average Shares Outstanding | 205.66 Million | 222.07 Million | 222.07 Million |
| Weighted Average Shares Outstanding (Diluted) | 205.66 Million | 222.07 Million | 222.07 Million |
| Gross Margin | 1.00 | -2.68 | -0.45 |
| EBIT Margin | -32.82 | -36.50 | -9.88 |
| Profit Margin | -34.42 | -35.89 | -16.84 |
| EBITDA | -484.12 Million | -275.04 Million | -149.45 Million |
| Earnings Before Tax Margin | -34.20 | -40.18 | -11.33 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 22.45 Million | 22.45 Million | 9.71 Million | 14.75 Million | - | - |
| Cost of Revenue | 3.58 Million | 3.58 Million | 8.86 Million | 35.67 Million | - | - |
| Gross Profit | 18.87 Million | 18.87 Million | 852.81 Thousand | -20.92 Million | - | - |
| Operating Expenses | 103.49 Million | 103.49 Million | 145.15 Million | 548.86 Million | 117.9 Million | 128.89 Million |
| Selling, General and Administrative Expenses | 35.16 Million | 35.16 Million | 40.63 Million | - | -76.16 Million | 49.38 Million |
| Research and Development Expenses | 72.61 Million | 72.61 Million | 104.52 Million | - | 94.42 Million | 84.42 Million |
| Other Expenses | -4.28 Million | -4.28 Million | 460 Thousand | 1.14 Million | 417 Thousand | -4.91 Million |
| Cost and Expenses | 107.07 Million | 107.07 Million | 154.02 Million | 584.54 Million | 117.9 Million | 128.89 Million |
| Operating Income | -84.61 Million | -84.61 Million | -154.02 Million | -584.54 Million | -115.53 Million | -128.89 Million |
| Interest Expense | - | - | 4.57 Million | 16.82 Million | 4.35 Million | - |
| Income Tax Expense | 18.5 Thousand | 18.5 Thousand | -19.45 Thousand | -80.66 Thousand | -18 Thousand | 18.5 Thousand |
| Earnings before Tax | -91.58 Million | -91.58 Million | -146.77 Million | -576.07 Million | -119.88 Million | -132.83 Million |
| Net Income | -86.05 Million | -86.05 Million | -144.6 Million | -561.06 Million | -115.91 Million | -129.03 Million |
| Earnings Per Share Basic | -0.40 | -0.40 | -0.65 | - | -0.52 | -0.64 |
| Earnings Per Share Diluted | -0.40 | -0.40 | -0.65 | - | -0.52 | -0.64 |
| Weighted Average Shares Outstanding | 216.77 Million | 216.77 Million | 222.07 Million | 222.07 Million | 222.07 Million | 201.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 216.77 Million | 216.77 Million | 222.07 Million | 222.07 Million | 222.07 Million | 201.23 Million |
| Gross Margin | 0.84 | 0.84 | 0.09 | -1.42 | - | - |
| EBIT Margin | -3.58 | -3.58 | -14.94 | - | - | - |
| Profit Margin | -3.83 | -3.83 | -14.88 | -38.04 | - | - |
| EBITDA | -80.43 Million | -80.43 Million | -145.15 Million | - | -116.74 Million | -124.53 Million |
| Earnings Before Tax Margin | -3.77 | -3.77 | -15.85 | -39.63 | - | - |
1796
SPHRF
PEG
MITPF
PNSE
ORLCF